REG - hVIVO PLC - Appointment of Independent Non-Executive Director

hVIVOAnnouncement

29/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250529:nRSc5012Ka&default-theme=true

RNS Number : 5012K  hVIVO PLC  29 May 2025

 

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

Directorate Change

Appointment of Independent Non-Executive Director

 

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and
the world leader in human challenge clinical trials, announces that further to
its announcement on 12 May 2025, the Company has appointed Tracey James as
Independent Non-Executive Director from 1 June 2025. Tracey will be Chair of
the Audit Committee, and a member of the Remuneration and Nominations
Committees.

 

Tracey is a Chartered Accountant with 26 years' experience working at Grant
Thornton UK LLP (Grant Thornton), including 14 years as an Audit Partner.
Tracey was a member of Grant Thornton's Oversight Board and also served on the
Audit & Risk and Pensions Committees. She has held roles as Director of
Finance at Karl Storz Endoscopy Canada, as Senior Independent Director, and
Chair of Audit at CT Automotive Group plc and as Vice Chair and Chair of Audit
& Risk and a member of the Remuneration Committee at Activate Learning
Group. Tracey was also Non-Executive Director and member of the Audit
Committee at Places for People Group.

 

Currently Tracey is a Non-Executive Director at ECO Animal Health Group plc
and Gattaca plc. She is also Chair of the Audit & Risk Committee and a
member of the Remuneration Committee for both companies.

 

Yamin 'Mo' Khan, Chief Executive Officer of hVIVO plc, said: "We ae delighted
to welcome Tracey to the Board of hVIVO. Tracey brings with her a wealth of
experience, especially with AIM listed companies, that will further strengthen
the Board. I look forward to working with Tracey and leaning on her expertise
as we continue to integrate our diverse portfolio of revenue streams and
deliver further progress for our clients and shareholders."

 

 

 

Tracey James

Independent Non-Executive Director

 

 

 

 

Additional Information on the Board Appointment

 

The following additional information is provided with regards to the
appointment of Tracey Dawn James (née Clements), aged 62, in accordance with
Rule 17 and Schedule 2(g) of the AIM Rules for Companies:

 

 Current directorships/partnerships:  Former directorships/partnerships (within the last five years):
 ECO Animal Health Group plc          Activate Learning Group (Charity)
 Gattaca plc                          Allenbuild Limited
                                      CT Automotive Group plc
                                      Millwood Designer Homes Limited
                                      Modularwise Limited
                                      Places for People Developments Limited
                                      Places for People Group Limited
                                      Places for People Ventures Limited
                                      Places for People Ventures Operations Limited
                                      Zeroc Group (2008) Limited

 

Tracey does not hold any shares or options in the Company.

 

There are no further disclosures required under Rule 17 and Schedule 2(g) of
the AIM Rules for Companies.

 

For further information please contact:

 

 hVIVO plc                                       +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                  +44 (0)20 7220 0500
 Geoff Nash, Callum Davidson

Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                        +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                 +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0)20 7933 8780 or hvivo@walbrookpr.com

 Paul McManus / Alice Woodings                   +44 (0)7980 541 893 / +44 (0)7407 804 654

 Lianne Applegarth                               +44 (0)7584 391 303

 

 

 

Notes to Editors

 

hVIVO plc (https://hvivo.com/) (Ticker: HVO) is full-service Contract Research
Organisation (CRO) and the global leader in human challenge trials. The
company delivers end-to-end clinical development services to a diverse and
expanding client base, including seven of the world's ten largest biopharma
companies.

 

hVIVO specialises in conducting human challenge trials across multiple
infectious and respiratory indications, leveraging its state-of-the-art
quarantine facility in London-the largest of its kind worldwide. The company
also offers comprehensive virology and immunology laboratory services under
the hLAB (https://hlabservices.com/) brand.

 

Through its German subsidiary, CRS (https://crs-earlyphase.com/) , hVIVO
operates a 120-bed capacity across Mannheim and Kiel, providing early-phase
clinical trial services, including first-in-human and proof-of-concept
studies. Its second subsidiary, Venn Life Sciences
(https://www.vennlifesciences.com/) , offers Early Drug Development Consulting
and Biometry services to the biopharma sector.

 

The Group provides fully integrated drug development solutions from
preclinical stages through Phase II trials, alongside patient recruitment via
FluCamp (https://flucamp.com/) . Additionally, its five clinical sites support
outpatient Phase II and III trials, ensuring a seamless and efficient pathway
from discovery to late-stage development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUUCAUPAGRR